Corcept Therapeutics (NASDAQ:CORT) Director Sells 103,606 Shares
Corcept Therapeutics Director David Mahoney sold 103,606 shares for approximately $12.25 million, reducing his stake by 8.37%. The company's shares are trading near a 52-week high, with a market capitalization of $13.09 billion and a high P/E ratio. Recent earnings exceeded expectations, and analysts maintain a "Moderate Buy" consensus with an average price target of $138.17.
Lisanti Capital Growth LLC Takes Position in Corcept Therapeutics Incorporated $CORT
Lisanti Capital Growth LLC has acquired 91,610 shares of Corcept Therapeutics (CORT) valued at approximately $7.97 million, making it their fifth-largest holding. Institutional investors collectively own 93.61% of the company, while analyst sentiment is largely positive despite a recent downgrade by Wolfe Research. The company reported strong Q2 earnings, surpassing revenue and EPS estimates, but insiders have sold a significant amount of stock in the last three months.
Truist Financial Initiates Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $164
Truist Financial has initiated coverage on Corcept Therapeutics (CORT.US) with a Buy rating. The financial institution also announced a target price of $164 for the pharmaceutical company's stock.
Corcept Therapeutics (NASDAQ:CORT) Director James Wilson Sells 10,000 Shares of Stock
Corcept Therapeutics Director James Wilson sold 10,000 shares of CORT stock for over $1.11 million, reducing his stake by 0.92%. The company recently exceeded Q2 earnings and revenue expectations, reporting $0.36 EPS against a $0.02 consensus and $256.15 million in revenue. Analyst sentiment remains largely positive with a "Moderate Buy" consensus, despite one recent downgrade.
Corcept (NASDAQ: CORT) director sells 10,000 shares under 10b5-1 plan
Corcept (NASDAQ: CORT) director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, reported the indirect sale of 10,000 shares of common stock on August 14, 2026. These sales were conducted in multiple open-market transactions at weighted average prices between approximately $110 and $113 per share, pursuant to a pre-established Rule 10b5-1 trading plan adopted on March 12, 2026. Wilson disclaims beneficial ownership of the trust's shares except to the extent of his pecuniary interest, while separate grantor retained annuity trusts maintain indirect holdings of 200,000 shares each.
Corcept (NASDAQ: CORT) director plans open-market sale of 103,606 shares
A director at Corcept Therapeutics Inc. (NASDAQ: CORT), David L. Mahoney, has filed a Form 144 notice indicating a planned open-market sale of 103,606 shares of common stock. The shares, valued at approximately $12.16 million, were acquired through open market purchases between May 2020 and April 2024. The proposed sale is set to occur on or after August 18, 2026, subject to Rule 144 conditions.
Truist Adjusts Price Target on Corcept Therapeutics to $164 From $50, Maintains Buy Rating
Truist has significantly raised its price target for Corcept Therapeutics (CORT) to $164 from $50, while reiterating a Buy rating on the stock. This adjustment follows several positive updates for Corcept, including strong Q2 2026 earnings, increased revenue guidance for the full year, and the resubmission of their NDA for the Cushing's Syndrome treatment, Relacorilant. The company is actively engaged in developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders, with a focus on modulating the effects of cortisol.
Truist assumes Corcept Therapeutics stock with buy rating on Cushing’s opportunity
Truist Securities has initiated coverage on Corcept Therapeutics Inc. (NASDAQ:CORT) with a buy rating and a price target of $164, citing the significant opportunity in Cushing's disease and the potential of its drug relacorilant. The firm also highlighted Lifyorli, which received early approval for ovarian cancer and is viewed as a blockbuster opportunity with potential expansion into other solid tumors. This positive outlook follows Corcept Therapeutics' strong second-quarter 2026 financial results, which saw a 32% revenue increase and a raised full-year revenue outlook.
Corcept Therapeutics stock soars 228% after FDA support and tariff news boost shares.
Corcept Therapeutics' stock surged 228% to $117.17, driven by FDA backing for its drug relacorilant, positive clinical trial results showing a 35% reduction in death risk, and President Trump's announcement of continued zero-percent tariffs on imported generic drugs until 2026. This significant increase boosted President Trump's disclosed holdings in the company and elevated Corcept's market capitalization to $12.67 billion. The rally reflects favorable regulatory and trade developments for the pharmaceutical company.
CORCEPT THERAPEUTICS INC SEC Filing (Aug 17, 2026)
This article reports on a Form 144 SEC filing by CORCEPT THERAPEUTICS INC (CORT) dated August 17, 2026. The filing indicates a proposed sale of 10,000 shares of common stock with an aggregate market value of $1,162,572. The shares were acquired on December 31, 2025, through equity compensation and are to be sold via Stifel Nicolaus & Company Inc.
Corcept Therapeutics (CORT) Stock Looks Discounted On Sales But Premium Priced On Broader Checks
Corcept Therapeutics (CORT) stock has seen significant returns over the past five years, but current valuations suggest it may be expensive. While its Price/Sales ratio appears discounted compared to a tailored model, it trades at a premium to the broader pharmaceutical industry, indicating mixed signals for investors. The article highlights both bull and bear cases, emphasizing the importance of future revenue and margin performance in light of clinical, regulatory, and legal risks.
113,200 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Alberta Investment Management Corp
Alberta Investment Management Corp recently acquired 113,200 shares of Corcept Therapeutics (NASDAQ:CORT) for approximately $9.84 million, establishing a 0.10% stake in the company. Institutional investors collectively own 93.61% of Corcept, which reported strong quarterly earnings with EPS of $0.36 and revenue up 31.7% year-over-year. Analysts currently have a "Moderate Buy" rating for the stock, with an average price target of $119.17, although insiders have recently sold a significant number of shares.
CORT Looks 65.7% Overvalued on GF Value™
Corcept Therapeutics (CORT) has seen a significant stock gain of 228.94% year-to-date but is deemed 65.7% overvalued by GuruFocus' GF Value™ metric, trading at $114.47 against an intrinsic value of $69.10. Despite a strong GF Score™ of 85/100, reflecting robust growth and profitability, the company exhibits high insider selling and mixed guru ownership, suggesting caution for potential investors. Its P/E ratio of 272.55x significantly surpasses its five-year median of 30.53x, indicating high market expectations already priced into the stock.
23,257 Shares in Corcept Therapeutics Incorporated $CORT Purchased by GSA Capital Partners LLP
GSA Capital Partners LLP recently acquired a new position of 23,257 shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the second quarter, valued at approximately $2.022 million. Other institutional investors have also adjusted their holdings in CORT, with 93.61% of the stock owned by hedge funds and institutions. The article also notes recent insider selling activity and updated analyst ratings, with an average "Moderate Buy" rating and a target price of $119.17 for the biotechnology company.
Corcept therapeutics chief development officer sells $1.8m in stock
William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), sold shares worth approximately $1.85 million on August 10, 2026, through two separate transactions under a 10b5-1 plan. Despite the sales, which occurred while the stock was near its 52-week high, Guyer also acquired shares through stock option exercises and retains significant holdings including unvested restricted stock awards and stock options. This comes after Corcept reported strong Q2 2026 financial results with a 32% revenue increase and an updated full-year outlook, leading to an analyst price target upgrade.
Corcept Therapeutics (CORT) CBO reports 17,530-share stock gifts and trust holdings
Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported several bona fide gift transactions involving 17,530 shares of the company's common stock on August 12, 2026. These transactions included a direct gift disposition of 11,530 shares and gifts of 3,000 shares each to two custodial accounts for his children. Additionally, the filing updated his indirect holding of 49,716 shares through the Gary Charles Robb TTE Robb Revocable Trust.
Renaissance Technologies (CORT) discloses 4.90% beneficial stake in Corcept Therapeutics
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 4.90% in Corcept Therapeutics Inc., amounting to 5,261,628 shares of common stock. This Schedule 13G/A filing indicates that Renaissance Technologies holds sole voting and dispositive power over these shares. Certain funds managed by Renaissance Technologies LLC are entitled to receive dividends and proceeds from the sale of these securities.
Corcept chief development officer sells $418,561 of stock
Corcept Therapeutics Inc.'s Chief Development Officer, William Guyer, sold 3,700 shares of the company's stock for $418,561, while simultaneously acquiring the same number of shares through stock options for $80,105. This transaction comes as Corcept's stock has seen significant gains, trading near its 52-week high with a 192% increase over the past six months, and follows a strong second-quarter performance that led to an increased full-year revenue forecast.
Sean Maduck Sells 1,031 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock
Sean Maduck, an insider at Corcept Therapeutics (NASDAQ:CORT), sold 1,031 shares of the company's stock on August 10th, valued at approximately $118,070, reducing his holdings by 9.56%. This sale is part of a series of transactions by Maduck in recent months. The company recently reported strong quarterly results, with EPS of $0.36 and revenue up 31.7% year-over-year, while analysts maintain a "Moderate Buy" rating for the stock despite its high price-to-earnings ratio.
William Guyer Sells 16,300 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock
William Guyer, an insider at Corcept Therapeutics, sold 16,300 shares of the company's stock for approximately $1.85 million, reducing his direct ownership by over 80%. This sale follows other transactions made by Guyer since June. The company recently reported strong quarterly results with revenue up 31.7% year-over-year and EPS of $0.36, significantly beating analyst estimates.
Corcept chief development officer sells $418,561 of stock
Corcept Therapeutics Inc.'s Chief Development Officer, William Guyer, sold 3,700 shares of common stock for $418,561 and simultaneously acquired 3,700 shares through option exercises for $80,105 on August 4, 2026. These transactions occurred as the company's stock trades near its 52-week high, having gained significantly over the past year. The company recently reported strong Q2 2026 financial results, exceeding market expectations and prompting an increased full-year revenue forecast.
Sei Investments Co. Sells 62,377 Shares of Corcept Therapeutics Incorporated $CORT
Sei Investments Co. reduced its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 65.8% in the first quarter, selling 62,377 shares. Other institutional investors, including First Trust Advisors LP, AQR Capital Management LLC, and Geode Capital Management LLC, either increased their positions or bought new shares in the biotechnology company. Corcept Therapeutics recently exceeded analyst earnings expectations and several Wall Street analysts have issued ratings ranging from "Strong Buy" to "Underperform" for the stock.
Amundi Acquires New Shares in Corcept Therapeutics Incorporated $CORT
Amundi acquired 11,392 shares of Corcept Therapeutics (CORT) in the first quarter, valued at $459,000, adding to the 93.61% institutional ownership of the company. Despite significant insider selling totaling $33.15 million over the past 90 days, Corcept reported strong quarterly earnings of $0.36 EPS, surpassing estimates, and a 31.7% year-over-year revenue increase to $256.15 million. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $119.17 for the biotechnology firm.
Upgraded 2026 Revenue Outlook And Buybacks Might Change The Case For Investing In Corcept (CORT)
Corcept Therapeutics reported increased net income in Q2 2026 and raised its full-year 2026 revenue guidance to US$1.10–1.20 billion, along with completing a share repurchase program. This updated outlook, driven by confidence in its cortisol-modulation portfolio and new indications, signals a potential shift in its investment narrative. However, the company also faces risks from increased spending to support growth and ongoing legal/pricing pressures on Korlym.
Corcept Therapeutics Incorporat (CORT) Stock Forecasts
Argus has raised its target price for Corcept Therapeutics Inc (CORT) to $115.00, noting the company's focus on developing medications for severe metabolic, oncologic, and neuropsychiatric disorders. The current price for CORT is $111.86. The report emphasizes the company's commercial-stage pharmaceutical operations.
California State Teachers Retirement System Boosts Stake in Corcept Therapeutics Incorporated $CORT
The California State Teachers Retirement System increased its stake in Corcept Therapeutics (NASDAQ:CORT) by 23.1% in the first quarter, bringing its total to 110,829 shares valued at $4.47 million. The company reported strong Q1 earnings with EPS of $0.36 and revenue up 31.7% year-over-year, significantly beating analyst estimates. Despite positive institutional investment and a "Moderate Buy" consensus rating from analysts, company insiders have shown significant selling activity.
12,478 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Evanson Financial LLC
Evanson Financial LLC recently acquired 12,478 shares of Corcept Therapeutics (NASDAQ:CORT) worth approximately $1.085 million. This purchase is part of broader institutional investor activity, with hedge funds owning 93.61% of the company's stock. Despite some analyst downgrades and insider selling, the company recently beat quarterly earnings and revenue expectations.
Corcept Therapeutics Incorporat (CORT) Stock forecasts
Argus has raised its target price for Corcept Therapeutics Inc (CORT) to $100.00. The company is a commercial-stage pharmaceutical firm focused on developing medications for metabolic, oncologic, and neuropsychiatric disorders by modulating cortisol's effect. The current price of CORT stock is $110.77.
Corcept Therapeutics (CORT) Lifted Guidance, Is The Upside Already Priced In?
Corcept Therapeutics (CORT) is gaining attention after its Q2 earnings report, which included increased full-year 2026 revenue guidance and a share buyback update. While the stock has shown significant positive momentum over the long term, Simply Wall St's analysis suggests it is currently 23% overvalued at $107.95 compared to a narrative fair value of $88.00. The company faces potential upside from new drug approvals and commercial scaling, but also risks from patent litigation and Korlym pricing pressure.
Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells 3,700 Shares
Corcept Therapeutics insider William Guyer sold 3,700 shares of the company's stock for $418,544 on August 4th, reducing his ownership by 48.15%. This sale follows previous transactions in June and July. Despite the insider selling, Corcept Therapeutics reported strong quarterly earnings, beating consensus estimates with $0.36 EPS and a 31.7% year-over-year revenue increase.
Corcept CDO William Guyer sells $418,561 in common stock
William Guyer, Chief Development Officer at Corcept Therapeutics Inc., sold 3,700 shares of common stock for $418,561 on August 4, 2026, while also acquiring 3,700 shares by exercising stock options. This sale, conducted under a pre-arranged 10b5-1 plan, follows a significant 210% year-to-date surge in CORT shares. The company recently reported strong Q2 2026 financial results, including a 32% revenue increase and an upward revision of its full-year outlook.
Corcept Therapeutics (CORT) Lifted Guidance, Is The Upside Already Priced In?
Corcept Therapeutics (CORT) has seen its stock gain significant momentum after lifting its full-year 2026 revenue guidance following its Q2 earnings report. Despite strong long-term performance and potential for future growth from new drug approvals, Simply Wall St's narrative suggests the stock is currently 23% overvalued at $107.95 compared to a fair value of $88.00, highlighting mixed sentiment due to ongoing patent litigation and pricing pressures on its existing product.
Corcept CDO William Guyer sells $418,561 in common stock By Investing.com
William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), sold 3,700 shares of company stock for $418,561, while simultaneously exercising stock options to acquire the same number of shares. The sale followed a significant 210% surge in CORT shares year-to-date. This transaction was part of a pre-arranged trading plan, and Guyer continues to hold common stock and stock options in the company.
Corcept Therapeutics (CORT) Stock Could Be Undervalued Despite Mixed Broader Checks
Corcept Therapeutics (CORT) stock has seen significant returns over the past five years, but its current valuation suggests it's not an obvious bargain. While broader metrics show the stock leaning towards expensive, a tailored Price/Sales (P/S) ratio indicates it may be undervalued, especially after recent positive news regarding Lifyorli approval and updated revenue guidance. The article highlights a split in community opinion, with bulls focusing on pipeline potential and bears on declining net income despite revenue growth, making execution on new programs crucial for future valuation.
Corcept Therapeutics (CORT) Stock Could Be Undervalued Despite Mixed Broader Checks
Corcept Therapeutics (CORT) has shown significant returns over the last five years, but its current valuation presents a mixed picture. While a tailored P/S ratio suggests the stock might be undervalued, broader metrics indicate it's not a clear bargain. The company's future performance hinges on converting its pipeline and recent product approvals into sustained growth without compromising profits.
We Think That There Are More Issues For Corcept Therapeutics (NASDAQ:CORT) Than Just Sluggish Earnings
Corcept Therapeutics (NASDAQ:CORT) recently reported lackluster earnings, but its stock price rose due to underlying positive factors. The company shows a strong accrual ratio of -0.15, indicating free cash flow significantly exceeding statutory profit, and benefited from an unusual tax credit of US$29 million. Despite the tax benefit boosting current profits, it suggests that future statutory profits might not be as high without continued strong growth or recurring one-off factors.
Corcept Therapeutics' (NASDAQ:CORT) Anemic Earnings Might Be Worse Than You Think
This article analyzes Corcept Therapeutics' recent financial performance, highlighting concerns about its declining profit margins and low shareholder returns despite revenue growth. The company's reliance on a single drug, Korlym, and increased R&D and selling expenses are identified as key factors contributing to its anemic earnings, potentially leading to future underperformance if not addressed.
CORT (NASDAQ: CORT) insider schedules 20,000-share option-related sale
Corcept Therapeutics (NASDAQ: CORT) has filed a Form 144 indicating a planned sale of 20,000 shares of common stock by insider William Guyer, valued at $2,256,000. This sale, scheduled for August 4, 2026, is related to a stock option exercise. Guyer has made similar 20,000-share sales in May, June, and July of 2026, with increasing proceeds from each transaction.
Corcept Therapeutics Stock Shines at New All-Time Highs Despite Its Valuation
Corcept Therapeutics (CORT) has seen its stock reach new all-time highs, with shares up over 50% in the past year, driven by strong fundamentals and bullish technical indicators. Despite its high valuation and mixed analyst sentiment, the company is projected to see significant growth in revenue and earnings. The article recommends careful investment due to the stock's volatility.
Why Corcept Therapeutics (CORT) Is Up 19.8% After Boosting 2026 Revenue Guidance And Earnings
Corcept Therapeutics (CORT) saw its stock rise by 19.8% after reporting strong second-quarter 2026 net income of US$42.99 million and raising its full-year 2026 revenue guidance to between US$1.1 billion and US$1.2 billion. This upward revision reflects management's confidence in its business momentum, despite ongoing concentration risk around its drug Korlym and regulatory uncertainties for relacorilant. The article also touches on analyst forecasts and various fair value estimates for the company.
Form 144 CORCEPT THERAPEUTICS INC For: 3 August By Investing.com
This article announces the filing of Form 144 by Corcept Therapeutics Inc. for August 3rd. It is a brief, direct notification published by Investing.com, likely indicating an insider's intent to sell restricted stock. The publication features standard stock market data, indices, and news headlines from Investing.com.
CORCEPT THERAPEUTICS INC SEC Filing (Aug 3, 2026)
This article reports on a Form 144 SEC filing by CORCEPT THERAPEUTICS INC (CORT) dated August 3, 2026. The filing indicates a proposed sale of securities, specifically 1540 shares of common stock with an aggregate market value of $175,806.00, acquired through option exercises. The document details the filer and issuer information, the securities to be sold, and confirms that no securities were sold in the past three months by the person making this notice.
John Hussman's Top Q2 2026 Move: Exiting Corcept Therapeutics Inc at a -1.1% Portfolio Impact
John Hussman's Hussman Strategic Advisors' Q2 2026 13F filing indicates a defensive shift in his portfolio strategy. He completely exited Corcept Therapeutics Inc, resulting in a -1.1% portfolio impact, while making significant new buys in Teradata Corp and PACS Group Inc, and increasing stakes in companies like PepsiCo Inc. This repositioning reflects Hussman's valuation-driven approach and cautious stance in navigating market conditions.
Form 144 CORCEPT THERAPEUTICS INC For: 3 August By Investing.com
Investing.com reported on August 3, 2026, about a Form 144 filing for CORCEPT THERAPEUTICS INC. The article is very brief, providing only the title and publication details, along with market data and popular news headlines. It does not elaborate on the specifics of the Form 144 filing.
Corcept Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
Corcept Therapeutics (NASDAQ: CORT) had approximately 753 total employees worldwide as of March 2026, marking a 125.5% growth from 2023. The company is actively hiring, despite a 22.5% decline in active job postings from 2025 to 2026. Most of its workforce is concentrated in North America, with an average salary of $205,258.
CORCEPT THERAPEUTICS INC 2Q 2026: Revenue $256.15M, EPS $0.36— 10-Q Summary
CORCEPT THERAPEUTICS INC reported strong second-quarter 2026 results, with product revenue reaching $256.15M, net income of $42.14M, and diluted EPS of $0.36, all showing significant year-over-year growth. This performance was driven by the commercial launch of Lifyorli for platinum-resistant ovarian cancer and continued growth in their Hypercortisolism Products, supported by positive trial data and strategic market expansion. The company is increasing investment in sales and marketing while advancing its R&D pipeline in oncology, ALS, MASH, and new modulators.
Corcept Therapeutics (CORT) affiliate files to sell 40,000 shares after option exercise
An affiliate of Corcept Therapeutics (CORT), Atabak Mokari, has filed a notice to sell 40,000 shares of common stock through Stifel Nicolaus & Company on or about July 30, 2026, on Nasdaq. These shares relate to stock option exercises from February 13, 2023. This filing also details previous sales by Mokari, including 40,000 shares each on June 1, June 15, and July 15, 2026, with increasing proceeds from each transaction.
S&P 500 Futures Rise in Premarket Trading; Corcept Therapeutics, FormFactor Lead
S&P 500 futures showed an increase in premarket trading, with Corcept Therapeutics Inc. (CORT) and FormFactor Inc. (FORM) leading the gains. Corcept Therapeutics was up 21.3% and FormFactor was up 16.4% ahead of the market open. The article highlights these two companies as top movers before the U.S. stock markets officially open.
Corcept: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for Corcept. Due to the brevity of the original content, no further details about the earnings are available.
Corcept Therapeutics stock hits 52-week high at 112.0 USD
Corcept Therapeutics' stock hit a new 52-week high of $112.00, driven by strong market sentiment and exceptional year-to-date gains of 167%. Despite appearing overvalued by InvestingPro analysis, the company reported robust Q2 2026 revenues of $256 million, a 32% year-over-year increase, and raised its full-year guidance, leading H.C. Wainwright to maintain a 'Buy' rating.
